6 unchanged sentences
Amended and Restated Bylaws
−Removed: Equity Purchase Agreement, dated as of June 18, 2019 by and among Ultragenyx Pharmaceutical Inc.
−Removed: and Arcturus Therapeutics Ltd.
−Removed: Third Amendment, dated as of July 29, 2019, to the Lease Agreement dated as of October 30, 2015 by and between Ultragenyx Pharmaceutical Inc.
−Removed: and ARE-MA Region No., LLC.
−Removed: Fourth Amendment, dated as of March 31, 2020, to the Lease Agreement dated as of October 30, 2015 by and between Ultragenyx Pharmaceutical Inc.
−Removed: and ARE-MA Region No., LLC.
+Added: Offer Letter between Mardi C.
+Added: Dier and Ultragenyx Pharmaceutical Inc.
+Added: dated August 28, 2020.
+Added: Amendment dated October 9, 2020 to the Offer Letter between Mardi C.
+Added: Dier and Ultragenyx Pharmaceutical Inc.
+Added: dated August 28, 2020
+Added: Amendment, dated as of August 28, 2020, to Transition Letter Agreement between Shalini Sharp and Ultragenyx Pharmaceutical Inc.
+Added: dated March 5, 2020.
+Added: Amendment No.
+Added: 2 dated October 8, 2020 to the Transition Letter Agreement between Shalini Sharp and Ultragenyx Pharmaceutical Inc.
+Added: dated as of March 5, 2020, as amended on August 28, 2020
+Added: Fourth Amended and Restated Amendment to Lease Agreement between Ultragenyx Pharmaceutical Inc.
+Added: and ARE-MA Region No.
Certification of Principal Executive Officer Required Under Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act
7 unchanged sentences
Inline XBRL Taxonomy Extension Presentation Linkbase Document
−Removed: The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, formatted in Inline XBRL (included in Exhibit 101).
+Added: Cover Page Interactive Data File, formatted in Inline XBRL (included in Exhibit 101).
* The certification attached as Exhibit 32.1 that accompanies this Quarterly Report is furnished to, and not deemed filed with, the SEC and is not to be incorporated by reference into any filing of the Registrant under the Securities Act or the Exchange Act, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing.
1 unchanged sentence
ULTRAGENYX PHARMACEUTICAL I NC .
−Removed: July 30, 2020
+Added: October 27, 2020
Kakkis, M.D., Ph.D.
1 unchanged sentence
(Duly Authorized Officer)
−Removed: July 30, 2020
−Removed: /s/ Shalini Sharp
−Removed: Shalini Sharp
−Removed: Executive Vice President and Chief Financial Officer
−Removed: (Principal Financial Officer)
−Removed: July 30, 2020
+Added: October 27, 2020
/s/ Theodore A.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.